24.08.2020
To the attention of Contract Research Organisations
In the context of the COVID-19 pandemic, the NAMMDR stated on 17.03.2020 that it considers prioritization of the assessment of clinical trials with medicinal products for the treatment of the COVID-19 infection. Given the large number of requests, the expected deadline for completion of the assessment of a COVID-19 trial is changing and will be of 14 to maximum 21 calendar days (Phase III trials shall be considered a priority).
Please note that, for this type of trials as well, the NAMMDR encourages the use of the EU coordinated assessment through the VHP procedure; in this case, the procedure timetable will be established in agreement with the other Member States.